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PAnxiety Worsens Prognosis in
Patients With Coronary Artery Disease
Woldecherkos A. Shibeshi, MD,*† Yinong Young-Xu, SCD, MS, MA,* Charles M. Blatt, MD, FACC*†
Brookline and Boston, Massachusetts
Objectives This study examined the effect of anxiety on mortality and nonfatal myocardial infarction (MI) in patients with
coronary artery disease (CAD).
Background Inconsistent data exist regarding the impact of anxiety on the prognosis of patients with CAD.
Methods The authors conducted a prospective cohort study at an outpatient cardiology clinic of 516 patients with CAD
(mean age 68 years at entry, 82% male) by administering the Kellner Symptom Questionnaire annually. The pri-
mary outcome was the composite of nonfatal MI or all-cause mortality.
Results During an average follow-up of 3.4 years, we documented 44 nonfatal MIs and 19 deaths. A high cumulative
anxiety score was associated with an increased risk of nonfatal MI or death. Comparing the highest to lowest
tertile of anxiety score, the age-adjusted hazard ratio was 1.97 (95% confidence interval 1.03 to 3.78, p 
0.04). In a multivariate Cox model after adjusting for age, gender, education, marital status, smoking, hyperten-
sion, diabetes mellitus, previous MI, body mass index, and total cholesterol, each unit increase in the cumulative
mean anxiety score was associated with increased risk of nonfatal MI or total mortality; the hazard ratio was
1.06 (95% confidence interval 1.01 to 1.12, p  0.02).
Conclusions A high level of anxiety maintained after CAD diagnosis constitutes a strong risk of MI or death among patients
with CAD. (J Am Coll Cardiol 2007;49:2021–7) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.007M
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prospective studies have implicated emotional distress as a
isk factor for the development of coronary artery disease
CAD) (1–3). Mental stress has been linked to the progres-
ion of atherosclerosis, development of atherothrombosis,
nd increased risk of arrhythmias (4–6). Among the
ifferent aspects of emotional distress, depression has
een extensively studied and is considered a major cardiac
isk factor (1,7,8). The role of anxiety as a prognostic
actor in the development of adverse cardiac events
mong patients with CAD is not well understood (1,8,9).
ost of the previous studies included just a single
aseline measurement of anxiety symptoms. Because a
ingle baseline measurement does not reflect long-term
nxiety, we hypothesized that a high or an increasing level
f anxiety that is maintained over an extended period is
ssociated with an increased risk of MI and death in patients
ith CAD.
rom the *Lown Cardiovascular Research Foundation, Brookline, Massachusetts, and
he †Harvard Medical School, Boston, Massachusetts. Supported in part by the Lown
ardiovascular Research Foundation, Brookline, Massachusetts.P
Manuscript received September 19, 2006; revised manuscript received January 19,
007, accepted February 5, 2007.ethods
tudy sample and enrollment. We prospectively studied a
ample of patients with CAD from an outpatient clinic
ffiliated with an academic medical center. Details of the
cientific rationale and characteristics of the study popula-
ion have been published previously (10,11).
Between December 1992 and April 2001, consecutive
atients with CAD were recruited to the study, including
en and women of all ages who met one or more of the
ollowing inclusion criteria: 1) a history of a documented
I; 2) angiographically proven CAD; 3) a history of typical
ngina with a positive exercise treadmill test with or without
uclear imagining; or 4) a history of atypical angina with a
ositive exercise treadmill test verified by abnormal nuclear
r echocardiographic imaging. Patients were excluded from
he study if they had previous coronary revascularization or
ad evidence of significant coexisting cardiac disease (val-
ular heart disease, cardiomyopathies, New York Heart
ssociation functional class III or IV heart failure) or
omorbid conditions that could significantly shorten life
pan and limit follow up (e.g., cancer).
After informed written consent was obtained from each
atient on study enrollment, data on sociodemographic,
sychosocial, and clinical characteristics were collected.
atients completed a questionnaire annually, either during
o
a
o
p
t
“
b
c
a
r
c
a
w
s
o
A
i
b
p
c
(

p
f
s
i
i
b
i
h
w
a
A
m
n
m
i
w
a
i
I
r
S
a
t
a
t
w
s
i
s
c
1
a
v
n
m
c
o
o
q
b
e
c
d
a
a
h
o
s
r
r
c
o
2
c
u
v
u
b
i
a
h
e

c
f
C
c
p
d
s
t
e
m
u
2022 Shibeshi et al. JACC Vol. 49, No. 20, 2007
Anxiety Worsens Prognosis for Heart Patients May 22, 2007:2021–7their scheduled clinic visit or by
mail. A cardiologist updated the
clinical data, including any in-
terim test results, after the sched-
uled visit.
Assessment of anxiety. We used
Kellner’s Symptom Questionnaire
(SQ) (12) to measure anxiety. In
addition to anxiety, SQ measures
depression, hostility, and somati-
zation, thus enabling the testing
f the independent prognostic value of anxiety. This self-
dministered questionnaire instructs subjects to answer each
f the 92 yes/no questions about their feelings during the
revious week (e.g., “feeling peaceful,” “feeling that some-
hing bad will happen,” “takes a long time to fall asleep,”
upset bowels or stomach,” and so on). The instrument has
een validated for its ability to discriminate between psy-
hiatric patients and normal patients, and for its test-retest
nd half-split reliabilities (12–14). Each subscale has scores
anging from 0 to 23 points. Anxiety scores 8 were
onsidered to be abnormally high (12). Because categorical
nalysis has clinical relevance and can detect graded effect,
e further divided anxiety scores into tertiles based on our
ample size and event rate, fitting the intuitive classification
f low, intermediate, and high level of anxiety.
ssessment of risk factors. At entry to the study, attend-
ng physicians collected data on variables that are known to
e strongly associated with the outcomes of interest and are
otential confounders, including age, gender, level of edu-
ation (below or above 12th grade), history of hypertension
those who were using antihypertensive medication or with
140 mm Hg systolic or 90 mm Hg diastolic blood
ressure), diabetes mellitus (those who were being treated
or diabetes or whose fasting blood sugar was 126 mg/dl),
moking (history of smoking or current smokers), alcohol
ntake (history of drinking, frequency, and amount), phys-
cal exercise (regularity and intensity). Blood pressure and
ody mass index were recorded, and laboratory data includ-
ng lipid profiles (total cholesterol, low-density lipoprotein,
igh-density lipoprotein, triglycerides) and blood sugar
ere obtained. These and other variables were measured
nnually during follow-up.
scertainment of nonfatal MI and mortality. The pri-
ary outcome of interest was the composite incidence of
onfatal MI or all-cause mortality. Secondary outcome
easures included nonfatal MI, cardiac death, total mortal-
ty, and unstable angina. Information on these outcomes
as periodically ascertained by the treating cardiologists
ccording to standard criteria, with additional review of
npatient and outpatient records by a research assistant.
nformation about death was obtained from medical
ecords, obituaries, and interviews with proxies.
tatistical analysis. Patients with baseline anxiety levels
nd at least 1 follow-up anxiety measure were included in
Abbreviations
and Acronyms
CAD  coronary artery
disease
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
SQ  The Kellner Symptom
Questionnairehe analyses. Among these patients, 7% of the follow-up rnxiety measures were missing and they were replaced using
he last observation carried forward method. Anxiety scores
ere then cumulatively averaged to assess long-term expo-
ure, starting with the first follow-up measure. For example,
f patient X had anxiety scores 5, 10, and 15 at her first,
econd, and third follow-up visits respectively, then the
umulative mean score at her third follow-up is 10 ([5 
0  15]/3). Cumulative mean scores were calculated until
n event (nonfatal MI or death) occurred, or until the last
isit if no event occurred. Consequently, a patient could
ever be counted twice in each analysis.
Kellner’s anxiety scores, both baseline and cumulative
ean, were dichotomized at a cutoff score of 8, and were
ategorized into tertiles with roughly one third of the
bservations in each tertile. We categorized this continuous
utcome because the SQ scale, like any other scale, is only
uasicontinuous and has an artificial lower and upper
oundary. Moreover, the categorization reduces the influ-
nce of outliers. Finally, although the cutoff points alone
annot and should not be used to make a psychiatric
iagnosis, we wanted to use the binary changes (normal vs.
bnormal) to capture substantial and qualitative changes in
ddition to numerical changes. The tertile categorization
as added benefits because it was based on the distribution
f our study population and could show a graded effect. The
lightly finer categorization (tertiles vs. binary) also helps to
ecover some of the statistical power that is lost by catego-
izing a continuous variable. Summary statistics of baseline
haracteristics in relation to tertiles of baseline anxiety scores
n the SQ scale (Table 1) and crude incidence rates (Table
) were provided. The association between an individual
ovariate measure and baseline anxiety scores was assessed
sing a chi-square test for categorical data and analysis of
ariance for continuous variables (Table 1).
Cox proportional hazard models were used to compute
nivariate, age-adjusted, and multivariate adjusted HRs for
oth primary and secondary outcome measures per unit
ncrease in anxiety scores (Tables 3, 4, and 5). Models were
djusted to the following baseline covariates: age, gender,
ypertension, diabetes mellitus, previous MI, smoking,
xercise (duration in min/day: 15, 15 to 30, 30 to 60, and
60), level of education (below or above 12th grade), total
holesterol, body mass index, alcohol use, and aspirin use.
Survival analyses (including Kaplan-Meier) were per-
ormed. Nonparametric survival analyses using the Mantel-
ox test, which estimates rate ratios, were performed to
ontrol for difference in duration of follow-up based on a
roportional hazards model. We used this test to assess
ifferences in effect estimates among the tertiles of anxiety
cores on outcome measures, and to evaluate the overall
rend (Tables 3 and 4). Bivariate and multivariate adjusted
ffect estimates were computed separately. After dichoto-
izing the data into high and low anxiety scores, similar
nadjusted and multivariate adjusted analyses using a Cox
egression model were performed.
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May 22, 2007:2021–7 Anxiety Worsens Prognosis for Heart PatientsBoth the baseline and cumulative mean follow-up anxiety
cores were evaluated to assess the effect of anxiety on the
omposite of nonfatal MI or total mortality based on a Cox
egression for equality of survival, and to contrast the power
f a single baseline measure against repeated measures.
tatistical significance was determined using the Cox re-
ression model with both baseline and mean follow-up
cores in the model and adjusting for the above covariates.
The HRs and 95% CIs were used to assess measurement
f effect, and statistical significance levels were determined
y two-tailed p values of 0.05. The Stata Statistical Software
or Professionals (version 8, Stata Corp., College Station,
exas) was used for these analyses.
aseline Characteristics of Study Population*
Table 1 Baseline Characteristics of Study Population*
Variables
Lower 3rd (0 to 4)
(n  201)
Gender
Male (%) 41.5
Female (%) 27.2
Age (yrs) 68.6 8.9
Education
High school graduate or less (%) 37.4
Regular exercise (%) 40.1
Alcohol drinking (%) 42.3
Smoking (ever) (%) 37.6
Angina (current) (%) 36.0
Body mass index (kg/m2) 26.9 3.9
History of
Hypertension (%) 39.3
Diabetes (%) 39.7
Previous myocardial infarction (%) 34.6
Blood pressure (mm Hg)
Systolic 131.0 19.0
Diastolic 76.2 12.0
Total cholesterol (mg/dl) 203.8 37.1
Low-density lipoprotein cholesterol (mg/dl) 126.0 34.3
High-density lipoprotein cholesterol (mg/dl) 40.3 11.1
Medication use
Aspirin (%) 39.1
Beta-blocker (%) 38.2
Angiotensin-converting enzyme inhibitor (%) 35.1
Baseline anxiety scores were assessed using a chi-square test for categorical data and analysis
Event Rates Per 1,000 Person-Years Accordingto Cumulative Mean Follow-Up Anxiety Score Cl
Table 2 Event Rates Per 1,000 Person-Yearto Cumulative Mean Follow-Up Anxi
Event Person-Year Events
Anxiety SQ range
(Mean SD)
Nonfatal MI or death 1,890 59
Nonfatal MI 1,890 44
Cardiac death 1,959 12
Total death 1,948 19
Unstable angina 1,689 120MI  myocardial infarction; SQ  The Kellner Symptom Questionnaire.esults
aseline characteristics and incidence rate. A total of 516
articipants (82% men), with an average age of 68 (9)
ears, completed a baseline anxiety measurement and com-
leted at least one follow-up psychometric evaluation. Base-
ine anxiety scores were lower among men and increased
ith age. The prevalence of other traditional CAD risk
actors (except for high-density lipoprotein cholesterol) was
imilar among the tertiles of anxiety scores at baseline
Table 1).
The mean duration of follow-up for patients in the study
as 3.4 years (range 1 to 5 years). Over a 5-year period, we
tiles of Baseline Anxiety Scores
p Value†
Middle 3rd (5 to 8)
(n  178)
Upper 3rd (9 to 23)
(n  137)
0.03
33.7 24.7
38.0 34.8
68.3 8.6 65.6 10.2 0.002
36.8 25.9 0.47
35.2 24.7 0.07
32.5 25.2 0.11
33.3 29.1 0.20
33.1 31.0 0.11
27.3 4.4 27.0 4.8 0.64
34.1 26.7 0.94
36.8 23.5 0.81
39.2 26.3 0.35
131.3 20.0 131.8 19.7 0.95
75.8 11.5 75.4 9.4 0.83
205.8 4.7 201.8 6.7 0.67
128.5 36.7 122.9 34.1 0.42
39.3 10.0 43.0 13.8 0.02
35.9 25.0 0.12
33.2 28.6 0.24
39.2 25.7 0.64
nce for continuous variables. †The p value is based on the difference among the 3 groups.
cation
ording
core Classification
Tertiles of Cumulative Mean Anxiety Score
Lower 3rd Middle 3rd Upper 3rd
0–2.5 2.6–6 6.1–23
(1.1 0.8) (4.3 1.1) (9.9 3.4)
25.2 27.4 44.0
17.8 21.6 32.5
5.7 2.8 11.0
8.6 7.0 14.8
43.7 81.8 95.8Terassifi
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ety S
(n)
d
1
a
C
n
n
a
2
m
M
f
m
U
m
s
a
m
c
o
C
e
1
o
t
l
t
a
p
t
h
RSM
*
h
u
§
a
RPA
*
h
u
§
a
RAM
*
h
u
2024 Shibeshi et al. JACC Vol. 49, No. 20, 2007
Anxiety Worsens Prognosis for Heart Patients May 22, 2007:2021–7ocumented 44 new or recurrent cases of nonfatal MI and
9 all-cause deaths (12 cardiac-related deaths) with an
nnualized incidence rate of 3.1 in 100 person-years (95%
I 2.4 to 4.0) for the primary outcome (composite of
onfatal MI or total mortality). The crude incidence rate of
onfatal MI or total death was higher in those who were in
higher tertile of cumulative mean anxiety scores (25.2,
7.4, and 44.0 per 1,000 person-years for being in the lower,
iddle, and upper tertiles, respectively) (Table 2). Kaplan-
eier survival analysis showed a greater cumulative event-
ree survival for those patients who had lower cumulative
ean anxiety scores (Fig. 1).
elationship Between the Cumulative Mean Anxietycore and the Primary Outco e (Nonfatalyocardial Infarction or All-Cause Mortality)
Table 3
Relationship Between the Cumulative Mean Anxiety
Score and the Primary Outcome (Nonfatal
Myocardial Infarction or All-Cause Mortality)
Model
Hazard Ratio
(95% Confidence Interval) p Value
Continuous anxiety score*
Age-adjusted 1.06 (1.01–1.12) 0.02
Multivariate-adjusted† 1.07 (1.02–1.13) 0.01
Tertiles of anxiety score‡
Age-adjusted
1st tertile Reference
2nd tertile 1.16 (0.59–2.30) 0.59
3rd tertile 1.97 (1.03–3.78) 0.04
Multivariate-adjusted§
1st tertile Reference
2nd tertile 1.46 (0.51–4.14) 0.48
3rd tertile 11.03 (1.61–75.36) 0.002
Dichotomous anxiety score (8)*
Age-adjusted 1.63 (0.91–2.95) 0.10
Multivariate-adjusted† 1.71 (0.92–3.21) 0.09
Based on Cox proportional hazards regression. †Adjusted for age, gender, education, smoking,
ypertension, diabetes, previous myocardial infarction, body mass index, total cholesterol, alcohol
se, and use of aspirin. ‡Based on Mantel-Cox test, rate ratio provided instead of hazard ratio.
Adjusted for age, education, smoking, hypertension, diabetes, previousmyocardial infarction, and
lcohol use.
elationship Between Baseline Anxiety Score andrimary Outcome (Nonfatal Myocardial Infarctio orll-C use Mortality)
Table 4
Relationship Between Baseline Anxiety Score and
Primary Outcome (Nonfatal Myocardial Infarction or
All-Cause Mortality)
Model
Hazard Ratio
(95% Confidence Interval) p Value
Continuous anxiety score*
Age-adjusted 0.97 (0.91–1.04) 0.40
Multivariate-adjusted† 0.97 (0.90–1.04) 0.36
Tertiles of anxiety score‡
Age-adjusted
Trend 0.90 (0.65–1.25) 0.54
Multivariate-adjusted§
Trend 1.56 (0.89–2.73) 0.12
Dichotomous anxiety score (8)*
Age-adjusted 1.09 (0.63–1.78) 0.76
Multivariate-adjusted† 1.15 (0.67–1.97) 0.61
Based on Cox proportional hazards regression. †Adjusted for age, gender, education, smoking,
ypertension, diabetes, previous myocardial infarction, body mass index, total cholesterol, alcohol
se, and use of aspirin. ‡Based on Mantel-Cox test, rate ratio provided instead of hazard ratio.
Adjusted for age, education, smoking, hypertension, diabetes, previousmyocardial infarction, and
lcohol use.nivariate and multivariate analyses results for the pri-
ary outcome. We entered the cumulative mean anxiety
core as a continuous variable in a Cox regression model,
nd computed the associated risk of nonfatal MI or total
ortality with each unit increase in the scores. The mean
umulative anxiety score significantly predicted the primary
utcome in a continuous model: age adjusted HR 1.06 (95%
I 1.01 to 1.12, p  0.02). In the multivariate model, the
ffect size was similar: adjusted HR 1.07 (95% CI 1.02 to
.13, p  0.01) (Table 3).
A significantly higher rate of nonfatal MI and death was
bserved in the tertile of patients with the highest cumula-
ive mean anxiety score as compared with the tertile with the
owest score. Age adjusted rate ratio was 1.97 (95% CI 1.03
o 3.78, p  0.04). Comparing the same groups after
djusting for age, gender, smoking, hypertension, diabetes,
revious MI, physical activity, education, and alcohol use,
he cardiac event rate remained significantly elevated for the
ighest tertile: rate ratio  11.03 (95% CI 1.61 to 75.36,
elationship Between Cumulative Mean Follow-Upnxiety Score and Cardiac Events and Totaortality
Table 5
Relationship Between Cumulative Mean Follow-Up
Anxiety Score and Cardiac Events and Total
Mortality
Model
Hazard Ratio
(95% Confidence Interval)* p Value
Nonfatal myocardial infarction
Age-adjusted 1.06 (1.00–1.33) 0.05
Adjusted† 1.07 (1.00–1.14) 0.06
Cardiac death
Age-adjusted 1.12 (1.01–1.25) 0.04
Adjusted† 1.15 (1.03–1.29) 0.01
Total mortality
Age-adjusted 1.08 (0.99–1.18) 0.09
Adjusted† 1.10 (0.99–1.22) 0.07
Unstable angina
Age-adjusted 1.07 (1.03–1.12) 0.001
Adjusted† 1.08 (1.04–1.13) 0.001
Based on Cox proportional hazards regression. †Adjusted for age, gender, education, smoking,
ypertension, diabetes, previous myocardial infarction, body mass index, total cholesterol, alcohol
se, and use of aspirin.
Figure 1 Kaplan-Meier Estimates of Adverse Events Probability
by Tertiles of Cumulative Mean Anxiety Score
Adverse events included all-cause mortality and
nonfatal myocardial infarction.
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May 22, 2007:2021–7 Anxiety Worsens Prognosis for Heart Patients 0.002) (Table 3). The Mantel-Cox model was used to
est for trend of graded increase of risk from the lowest to
he highest tertile, and it was significant (p  0.01). After
ichotomizing the cumulative mean anxiety score at the
redetermined cutoff point of 8 according to Kellner (12),
e observed an age-adjusted HR of 1.63 (95% CI 0.91 to
.96, p  0.1) and a multivariate adjusted HR of 1.71 (95%
I 0.92 to 3.21, p  0.09). Although the effect measures
till point to a higher risk associated with abnormally high
nxiety score, both HRs are significant at the 90% level
nstead of the usual 95% level, a loss of power that was
oreseen when we dichotomized this continuous variable.
Categorizing both baseline anxiety score and cumulative
ean follow-up score into tertiles, we estimated the event
ate of nonfatal MI or death for each tertile of anxiety at
aseline and during follow-up. These categorical analyses,
sing Cox regression, showed that patients who started at
he lowest levels of anxiety scores at baseline and whose
ean cumulative anxiety scores were increased to the
ighest tertile during follow-up had the highest event rate of
he primary outcome compared with all the other paired
ombination of categories such as those who started and
emained within the lowest tertile of scores or started in the
ighest tertile and moved to the lowest tertile (p  0.01)
Fig. 2).
In contrast, baseline anxiety score alone (per unit in-
rease) was not significant in either age or multivariate
djusted models in predicting the risk of adverse outcome
age-adjusted HR 0.97 [95% CI 0.91 to 1.04, p  0.40];
ultivariate-adjusted HR 0.97 [95% CI 0.90 to 1.04, p 
.36]) (Table 4). Trend analyses of baseline anxiety score
Figure 2 Adverse Event Rates by Tertiles of Anxiety Score
Adverse events included all-cause mortality and
nonfatal myocardial infarction.wertiles provided no evidence that baseline anxiety score
ould independently predict risk of nonfatal MI or death
Table 4). Additional analysis was performed in which both
aseline and cumulative mean of anxiety scores were in-
luded in the model, and we found that multiple measures
f anxiety can significantly predict the risk of adverse
utcome even after we adjusted for baseline anxiety
multivariate-adjusted HR 1.10 [95% CI 1.02 to 1.20, p 
.02]). Indeed, as is shown in Figure 2, part of the reason
hat repeated measures of anxiety could better predict
dverse outcome than a single baseline measure is that
epeated measures could capture the changes in anxiety
core (between baseline and follow-up measures) in addition
o capturing long-term exposure to high level of anxiety.
hen we included directly a change in the anxiety score
follow-up anxiety score  baseline anxiety score] in the
ox survival model, we found a similar result (multivariate-
djusted HR 1.10 [95% CI 1.04 to 1.16, p  0.001]).
econdary outcomes. In secondary analyses, we examined
he association between cumulative mean anxiety score and
eparately nonfatal MI, cardiac death, total mortality, and
nstable angina. The risk of cardiac death was significantly
igher for each unit increase of cumulative mean anxiety
core: age adjusted HR 1.12 (95% CI 1.01 to 1.25), p 
.04, and multivariate adjusted HR 1.15 (95% CI 1.03 to
.29), p  0.01. Looking at individual components of the
rimary outcome, the risk (per unit increase in anxiety score)
rended toward an increased event rate with statistical
ignificance hovering around the 95% level: multivariate
djusted HR 1.07 (95% CI 1.00 to 1.14, p  0.06) for
onfatal MI; 1.10 (95% CI 0.99 to 1.22, p  0.07) for total
ortality (Table 5).
There were 120 events of unstable angina during the
ollow-up period. Cumulative mean SQ score was associ-
ted with an increased rate of unstable angina: age adjusted
R 1.07 (95% CI 1.03 to 1.12, p 0.001) and multivariate
djusted HR 1.08 (95% CI 1.04 to 1.13, p 0.001) (Table 5).
iscussion
his prospective cohort study is the first to include repeated
easurements of anxiety in CAD patients during long-term
ollow-up. Multiple measures of anxiety were significantly
ssociated in a dose-dependent manner with a higher risk of
eath or nonfatal MI. Patients whose anxiety score in-
reased during follow-up had a significantly higher risk of
eveloping a primary adverse outcome when compared with
atients whose cumulative mean anxiety score did not differ
ignificantly from baseline, including those patients whose
nxiety scores remained elevated. Baseline anxiety scores
redicted neither primary nor secondary outcomes.
Repeated measures of anxiety were better predictors of
utcome than a single anxiety measure. This emphasizes the
oll that an escalating anxiety state may impart to patients
ith CAD (15–23). A single measurement of anxiety may
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Anxiety Worsens Prognosis for Heart Patients May 22, 2007:2021–7eveal little of this complex emotion that may be influenced
y the interaction between patient and physician as CAD is
anaged. In our study, patients with escalating anxiety
evels did not fare as well as patients with declining anxiety
evels over the course of study. This supports the contention
hat a key element of the ill-defined benefit of a calming
edside or office manner is that of allaying the anxiety of
atients with CAD. Unfortunately, our data do not provide
nsight into why a declining anxiety score over time imparts
rotection from MI or death, but they do provide a
uantitative assessment of the risk associated with escalating
nxiety levels. Although some studies also have shown an
ssociation between increased anxiety and a higher risk of
eath or MI (24–27) in patients with CAD, others failed to
nd such an association (20–23). Our prospective study
iffers from previous reports on anxiety in that it involved
epeated measures of anxiety of patients with stable CAD
ith a median duration of 5 years after diagnosis, whereas
ost previous studies measured anxiety only once within a
ew days to a few weeks after the diagnosis of CAD.
Central neural mediators of anxiety and cardiac vulnera-
ility to recurrent MI and death may be shared (28).
hronic stress can result in increased sympathetic outflow,
educed heart rate variability and baroreflex reactivity, as
ell as impaired vagal control, which have been linked to
ncreased cardiac mortality from ventricular arrhythmia and
udden cardiac death (29–34). Chronically elevated cate-
holamine levels have been shown to increase lipoprotein
ipase levels, induce hyperglycemia, elevate blood pressure
35–38), and increase platelet aggregation (39–41).
ther psychological factors. It is possible that other
sychological factors, particularly depression, could have
nteracted with anxiety and thus could have influenced the
elationship found between anxiety and heart disease by
revious studies. Unfortunately, differentiating these com-
lex interactions and determining the unique strength of
ach of these psychological factors is beyond what this study
esign permits. Nevertheless, it was important to learn
hether anxiety was an independent prognostic factor
mong all the psychological factors that we measured
depression, hostility, and somatization). As a result, these
actors and their interaction terms with anxiety were in-
luded in the multivariate models as covariates. In all 3
ases, we found that the interaction terms were not signif-
cant, and that anxiety continued to be a significant predic-
or of our primary outcome. Also, when all 3 factors were
ntered into the multivariate model together, anxiety was
till a significant predictor with an HR of 1.11 (95% CI 1.03
o 1.09, p  0.004, per unit increase in anxiety). The
rognostic value of anxiety seems to be independent of other
sychological factors. This finding is consistent with that of
study by Grace et al. (42). After correcting for depression
easure, they found that anxiety was a significant predictor
f recurrent ischemic and arrhythmic events in a cohort of
atients with diagnosed MI or unstable angina during a
2-month follow-up. implications. The clinical implication of our study is that
nxiety should now be considered a prognostic factor in
atients with CAD. Severity of anxiety could be used in risk
tratification, and periodic evaluation and treatment of the
nxiety state should be considered as part of the compre-
ensive management of coronary patients. More studies are
eeded to determine what screening method and what
utoff point to use. Interventional studies involving random-
zed clinical trials will also be necessary to establish causality
nd to determine whether appropriate medical and stand-
lone psychosocial interventions to reduce anxiety will result
n better clinical outcomes.
tudy limitations. It is possible that our findings occurred
y chance, as a result of a confounding variable or bias, but
everal considerations argue against a chance occurrence.
hese include the prospective nature of the study and the
elatively long duration of follow-up. The demonstration of
strong and dose-dependent relationship between anxiety
nd adverse cardiac events also argues against the likelihood
f a chance finding. The risk estimates for primary out-
omes have been relatively consistent, regardless of the
odels and the selected covariates, and all but a few are
tatistically significant. The cumulative mean anxiety score
ndependently predicted event rates after controlling for
otential confounders. Independent ascertainment of the
utcomes in this study by a treating physician and a nurse
ithout knowledge of the degree of exposure excludes
ifferential ascertainment bias.
The data must be interpreted in the context of the
tudy design and the possibility of some residual and
ncontrolled confounders. Certain covariates may poten-
ially be a part of the biological causal pathway attenu-
ting effect size. However, we addressed this issue by
imiting covariates entered into the multivariate models
o their baseline values. The other caveat is that because
f differences in demographic characteristics of the pop-
lation under study—the majority of our patients were
lderly men and of a higher socioeconomic status—these
esults may not be generalizable to some other popula-
ions. It is also unfortunate that we did not have measures
or quality of life.
onclusions
epeated measures of anxiety predicted the composite
utcome of nonfatal MI or death in patients with stable
AD. Baseline anxiety scores failed to predict these
utcomes, suggesting that assessing anxiety regularly over
he long term is necessary. Furthermore, the cumulative
ean score separately predicted cardiac death or unstable
ngina. Interventional studies in the form of randomized
linical trials to assess the efficacy of anxiety reducing
nterventions on outcomes are needed.
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